Skip to main content
Sumithira Vasu, MD, Hematology, Columbus, OH

SumithiraVasuMD

Hematology Columbus, OH

Blood Banking & Transfusion Medicine, Hematologic Oncology

Assistant Professor, Internal Medicine, Ohio State University COM

Dr. Vasu is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Vasu's full profile

Already have an account?

  • Office

    460 W 10th Ave
    Columbus, OH 43210
    Phone+1 614-293-8619
    Fax+1 614-293-6420

Education & Training

  • National Institutes of Health Clinical Center
    National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 2008 - 2011
  • National Institutes of Health Clinical Center
    National Institutes of Health Clinical CenterFellowship, Blood Banking/Transfusion Medicine, 2006 - 2008
  • St Vincent Hospital
    St Vincent HospitalResidency, Internal Medicine, 2003 - 2006
  • Thanjavur Medical College
    Thanjavur Medical CollegeClass of 2001

Certifications & Licensure

  • OH State Medical License
    OH State Medical License 2011 - 2025
  • MD State Medical License
    MD State Medical License 2006 - 2011
  • American Board of Internal Medicine Hematology

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013

Clinical Trials

Publications & Presentations

PubMed

Abstracts/Posters

  • Effect of Early Post Transplantation Tacrolimus Concentration on the Risk of Acute Graft-Versus-Host Disease in Allogenic Stem Cell Transplantation
    Sumithira Vasu, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • A Phase 2 Study of Glasdegib for the Treatment of Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients with High Risk of Post-Allogeneic Stem Cell Transplantat...
    Sumithira Vasu, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Genetic Alterations at Diagnosis Predict Outcome of AML Patients Age 60 or Older Undergoing Allogeneic Transplantation in First RemissionClinically Relevant Abstract
    Sumithira Vasu, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Lectures

  • BMT CTN 1803: Haploidentical Natural Killer Cells (CSTD002) to Prevent Post-Transplant Relapse in AML and MDS (NK-REALM) 
    61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019

Press Mentions

  • Genomic Features of AML in Patients over Age 60 Can Predict Success of Bone Marrow Stem Cell Transplant, Research Shows
    Genomic Features of AML in Patients over Age 60 Can Predict Success of Bone Marrow Stem Cell Transplant, Research ShowsDecember 6th, 2019
  • Ruxolitinib + Allogeneic Stem Cell Transplantation in AML
    Ruxolitinib + Allogeneic Stem Cell Transplantation in AMLSeptember 18th, 2017